Search
for
Sort by
Research 181–210 of 1000+
- Minoxidil: a comprehensive review
- Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients
- Hypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprost
- (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile, a potent androgen receptor antagonist for stimulating hair growth and reducing sebum production
- Mild-to-moderate COVID-19 is not associated with worsening of alopecia areata: A retrospective analysis of 32 patients
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- Chemical pharmacotherapy options for managing adult acne
- Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
- Low-dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series
- Novel therapies for alopecia areata: The era of rational drug development
- Hair Transplantation for Men and Women
- Treatment Patterns and Treatment Satisfaction Among Adults with Alopecia Areata in the United States
- Clinicopathological characteristics and treatment outcomes of fibrosing alopecia in a pattern distribution: A retrospective cohort study
- Dermoscopy of an osteonevus of Nanta
- Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- Estimation of health utility values for alopecia areata
- The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents with Alopecia Areata
- Alopecia Areata Treatment Patterns and Satisfaction: Results of a Real-World Cross-Sectional Survey in Europe
- Prescribing to save patients money: Ethical considerations
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications
- Health Utility of Facial Angiofibroma associated with Tuberous Sclerosis Complex
- Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib